Journal profile · Multiple
Clinical and Translational Medicine
ISSN 2001-1326 · Wiley · ENGLAND · Monthly · Founded 2012
Clinical and Translational Medicine: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 7.78; fully open access; APC about USD 3,640; median 88 days to acceptance (108 articles, last 24 months); acceptance rate 10% (journal website); 416 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical and Translational Medicine is published by Wiley and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis and Single-cell and spatial transcriptomics, together about 21.2% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Clinical and Translational Medicine (CTM) is an international, peer-reviewed, and open access journal with aims at promoting and accelerating the translation of preclinical research to a clinical application and the communication between basic and clinical scientists. The journal emphasizes clinical potential and application of new biotechnologies, biomaterials, bioengineering, disease-specific biomarkers, cellular and molecular medicine, omics science, bioinformatics, applied immunology, molecular imaging, drug discovery and development, and regulation and health policy. The journal is focused on the bench to bedside approach, favoring studies and clinical observations which generate hypotheses and questions relevant to the patient and disease, and guide the investigations of cellular and molecular medicine. Clinical and Translational Medicine welcomes submissions from clinicians, researchers, policy makers, and the industry. The journal covers all areas of clinical and translational medicine (CTM) but specializes in several Themed Topics: Education and Career Development CTM is a major platform to exchange the knowledge and experience of clinical and translational science to increase awareness and understanding of CTM about the innovation, development, and regulation through dissemination of educational and training resources, including Graduate Communication, Educational Experience, and Talent Introduction. Clinical Studies of Drugs and Devices CTM offers the priority to publish results of interventional and observational studies on responses of human participants to interventions, especially evidence-based data of the improvement, efficacy, safety, toxicity, and outcomes in participants during clinical trials. CTM highly encourages clinical trials of new interventions, e.g. drugs, devices, procedures, or changes to participants' behaviors. Target-Based Drug Discovery and Development Target-based drug discovery and development is a major part of CTM, including target-based screening and identification, validation of target disease-specificity and drugability, computational signs and biosynthesis, drug-specific biomarkers to monitor the efficacy, drug metabolism and pharmacokinetics, target drug optimization and translation into clinical therapy. One of the focuses is protein targets, including enzyme targets, cell-signaling receptors, structural proteins and regulatory factors. Clinical Bioinformatics This topic devotes to articles on the application of
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Xiangdong WangPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine7.3%
- Ferroptosis and cancer prognosisMedicine7.1%
- Single-cell and spatial transcriptomicsBiochemistry, Genetics and Molecular Biology6.9%
- Immune cells in cancerImmunology and Microbiology6.6%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6.2%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6.2%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.5%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPMCEmbasePublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.78LetPub ·
- Impact factor (publisher) 2025
- 7.9Publisher website ·
- Impact factor (publisher) 2022
- 10.6Publisher website ·
- CiteScore 2026-06
- 33.8LetPub ·
- CiteScore (publisher)
- 33.8Publisher website ·
- CiteScore (publisher) 2025
- 33.8Publisher website ·
- SJR 2026-06
- 2.78LetPub ·
- SNIP 2026-06
- 1.99LetPub ·
- h-index
- 106OpenAlex ·
- i10-index
- 1,442OpenAlex ·
- 2-year mean citedness
- 6.74OpenAlex ·
- Self-citation rate
- 1.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 315LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 381Publisher website ·
- Downloads per year (publisher) 2025
- 1,583,636Publisher website ·
Articles by year OpenAlex count · 2,990 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 281 | 281 | 166 |
| 2025 | 416 | 416 | 2,249 |
| 2024 | 441 | 441 | 5,255 |
| 2023 | 389 | 389 | 7,786 |
| 2022 | 500 | 500 | 13,031 |
| 2021 | 400 | 400 | 13,030 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
88 daysMedian, submission to acceptance · P25–P75 9 days – 124 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 108 articles with submission and acceptance dates (734 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4 weeksLetPub ·
- Acceptance rate (publisher)
- 10%Publisher website ·
- Acceptance rate (publisher) 2025
- 10%Publisher website ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to first decision 2025
- 7 daysPublisher website ·
- Submission to acceptance 2025
- 106 daysPublisher website ·
- Acceptance to publication 2025
- 15 daysPublisher website ·
- Submission to publication (journal-reported)
- about 4 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,640 / GBP 2,810 / EUR 3,150 | Yes | CC BY | |
| OpenAlex | USD 3,470 / EUR 3,000 / GBP 2,680 | — | — | |
| LetPub | USD 3,300 / GBP 2,550 / EUR 2,860 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Abstract
- ≤ 300 words
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
Article types accepted7
- editorialOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- invited lettersOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- letterOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- letter to the journalOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- original research articleOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- review articleOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
- short communicationOriginal Research Article Review Article Invited Letters Editorial Short Communication Letter to the JournalLength not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Peer review, Preprints
- Authorship Authorship
Abstract word limit: 300 words Model summary
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Statement
Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.
Source ↗Publisher website ·- Data availability Data availability
Data availability statement required for all accepted manuscripts Model summary
All accepted manuscripts are required to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data. Authors will be required to confirm adherence to the…
Source ↗Publisher website ·- Publication ethics Publication Ethics
Publication ethics: follows COPE core practices Model summary
This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices).
Source ↗Publisher website ·- License & copyright
Open access licensing: CC BY, author retains copyright Model summary
Clinical and Translational Medicine is an Open Access journal and accepted articles are published under Creative Commons Attribution License (CC BY). With CC BY, the author retains copyright and the public is allowed to reuse the content.
Source ↗Publisher website ·- Peer review Peer Review and Acceptance
Peer review type: single-blind peer review Model summary
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Papers will only be sent to review if the Editors determin…
Source ↗Publisher website ·- Preprints
Preprint policy: preprints not considered Model summary
Published or submitted preprints would not be considered by this journal.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2012
- ISSN
- 2001-1326
- Society / sponsor
- Shanghai
- Latest issue on the website
- Volume 16, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical and Translational Medicine
What CAS zone is Clinical and Translational Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical and Translational Medicine is in Zone 2 of Medicine, and in Zone 2 of the minor category Medicine, Research & Experimental / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical and Translational Medicine?
The latest impact factor listed by LetPub is 7.78; CiteScore 33.8, h-index 106.
How long does peer review take at Clinical and Translational Medicine?
Based on the dates recorded on 108 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 88 days (interquartile range 9–124 days); authors report an average review time of about 4 weeks; the journal's website gives an acceptance rate of 10% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical and Translational Medicine?
According to the journal's author guidelines: Abstract: ≤ 300 words; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Clinical and Translational Medicine?
According to LetPub and DOAJ records, Clinical and Translational Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PMC and Embase; that list has not been checked against each database.
Is Clinical and Translational Medicine open access, and what is the APC?
Clinical and Translational Medicine is a fully open-access journal. APC about USD 3,640.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .